Media
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
Article featured in Health Affairs
MEDIA
Value creators or financial destroyers? The potential of gene therapies to transform healthcare
Article featured in STAT
New research brief: Emerging market solutions for financing and reimbursement of gene therapies for sickle cell disease: Why do payment innovation?
The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. However, the high treatment costs, budget impact, and unique challenges of SCD create a need for payment innovation to ensure access and sustainability for all stakeholders.
Catalyst Implementation Brief: Understanding access issues for new therapies
This brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with a focus on addressing these challenges for the new sickle cell disease (SCD) therapies, Casgevy and Lyfgenia.
